


Our Pipeline

We are building a pipeline of *in vivo* and *ex vivo* therapies, as well as continuing to develop innovative modular platform capabilities.

Program	Approach	Research	Candidate Selection	IND-Enabling	Early-Stage Clinical	Late-Stage Clinical	Partner
In Vivo		CRISPR is the therapy					
NTLA-2001: Transthyretin Amyloidosis	Knockout	▶					LEAD Intellia THERAPEUTICS + REGENERON
NTLA-2002: Hereditary Angioedema	Knockout	▶					Intellia THERAPEUTICS
Hemophilia A and B	Insertion	▶					LEAD REGENERON + Intellia THERAPEUTICS
Research Programs	Knockout, Insertion, Consecutive Edits	▶					Intellia THERAPEUTICS
Research Programs	Various	▶					Intellia THERAPEUTICS + REGENERON**
Ex Vivo		CRISPR creates the therapy					
OTQ923 / HIX763: Sickle Cell Disease	HSC	▶					NOVARTIS + Intellia THERAPEUTICS***
NTLA-5001: Acute Myeloid Leukemia	WT-TCR	▶					Intellia THERAPEUTICS
Solid Tumors	WT-TCR	▶					Intellia THERAPEUTICS
Undisclosed Programs	Undisclosed	▶					Intellia THERAPEUTICS
Other Novartis Programs	CAR-T, HSC, OSC	Undisclosed					NOVARTIS + Intellia THERAPEUTICS***



* Lead development and commercial party

** Rights to certain *in vivo* targets

*** Milestones & royalties only

CAR-T: Chimeric Antigen Receptor T cells

HSC: Hematopoietic Stem Cells

OSC: Ocular Stem Cells

Last updated October 6, 2021